The Brief

A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in its phase 1 trial.

Researchers at the University of California said 21 out of 25 patients generated an immune response to cancer cells.

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal cancer is showing promising results, according to a recently published study.

Researchers from the University of California said patients "developed strong immune responses" to the new vaccine and "remained disease-free."

Phase 1 trial

Dig deeper:

The vaccine, called ELI-002 2P, showed evidence of triggering a powerful and lasting immune response.

It may also help prevent or delay cancer reg

See Full Page